Key result
Targeting microglial RAS potentially protects against cardiovascular disease by shifting cells toward a homeostatic state.
Why the study?
Emerging evidence highlights the renin-angiotensin system as a critical modulator of microglial activity and chronic neuroinflammation in neurodegenerative diseases, stroke, and hypertension.
Design
Literature review
Answers are grounded in this paper and cite their sources.
Should not yet change practice; leaves open validation of microglial RAS targeting in prospective trials.
Microglia, the resident immune cells of the central nervous system (CNS), play a pivotal role in monitoring neuronal activity, maintaining tissue homeostasis, and orchestrating immune responses. Under physiological conditions, microglia support neuronal survival and synaptic remodeling, in part through anti-inflammatory mechanisms and clearance of cellular debris. However, dysregulated microglial activation is implicated in a wide variety of pathologic states, including neurodegenerative diseases, stroke, and hypertension, largely through the induction of chronic neuroinflammation. Emerging evidence highlights the renin–angiotensin system (RAS) as a critical modulator of microglial activity. Microglia express most RAS components, including angiotensinogen, ACE, ACE2, AT 1 R, AT 2 R, and Mas1R, enabling local generation of angiotensin peptides and autocrine/paracrine signaling. Activation of AT 1 R leads toward pro-inflammatory reactive microglial phenotypes, characterized by elevated release of cytokines and reactive oxygen species, whereas AT 2 R and Mas1R signaling transitions toward more homeostatic anti-inflammatory phenotypes, supporting tissue repair and neuronal protection. Dysregulation of this balance contributes to chronic neuroinflammation and may impact autonomic nervous system activity, linking microglial RAS signaling to systemic homeostatic alterations. Here, we review current literature into the expression, regulation, and functional consequences of RAS components in microglia, highlighting each element expression and signaling as regulators of neuroimmune activity while attempting to move away from the outdated M1/M2 nomenclature. We also discuss the therapeutic potential of pharmacologically targeting microglial RAS to shift reactive microglia toward a more homeostatic state, offering a promising strategy to mitigate neuroinflammation and protect against neurodegenerative and cardiovascular pathologies. Collectively, understanding the microglial RAS provides new avenues for intervention in CNS diseases associated with chronic inflammation.
No takes yet. Share an insight, caveat, or question.
Mohan et al. (2026) studied this question. Targeting microglial RAS can shift their phenotype toward a homeostatic state, potentially mitigating neuroinflammation and protecting against neurodegenerative and cardiovascular diseases.
Synapse has enriched 10 related papers. Consider them for comparative context: